SecBot SecBot
COURT-RULING ·Filed Apr 13, 2026

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD
BULLISH
Impact 6/10
Horizonweeks Processed4mo ago CourtCourt Ruling · courtlistener.com
Court ruling (district)
Actionable Insight ▲ Bullish

The court's decision substantially narrows the antitrust case against Teva, removing several high-risk theories. This reduces the litigation overhang on the stock. However, the DAW campaign and PBM agreement claims survive, so discovery will continue. Monitor for summary judgment motions and any settlement discussions. The ruling is a clear positive for Teva but does not eliminate the case entirely.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$31.77
T+0 close · Apr 14, 2026 · via day close
Latest settled
+3.71%
T+60 · $32.95
Vs SPY
−5.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $31.77entry
  2. T+1 · 7mo ago −0.50%α −1.29% · $31.61
  3. T+5 · 7mo ago −1.51%α −2.90% · $31.29
  4. T+20 · 6mo ago +12.72%α +6.42% · $35.81
  5. T+60 · 4mo ago +3.71%α −5.28% · $32.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The District Court of New Jersey adopted a Special Master's Report and Recommendation, partially granting Teva's motion to dismiss Mylan's antitrust lawsuit over Copaxone. The court dismissed with prejudice several key allegations, including claims related to citizen petitions, ANDA litigation, market shift, and copay assistance, while allowing the DAW campaign, exclusionary PBM agreements, and the 2020 reclassification petition/lawsuit to proceed. This significantly narrows the scope of the litigation and reduces Teva's potential antitrust exposure.

Court Ruling Details

Ruling Date
Apr 13, 2026
Court
District Court, D. New Jersey
Court Level
District
Judge
Julien Xavier Neals
Case Type
antitrust
Ruling Type
motion to dismiss
Outcome
WIN: ruling favors this company
Precedent Risk
LOW

Key Facts

  • Court dismissed with prejudice allegations about 20mg citizen petitions, 20mg ANDA lawsuit, 2014 FDA lawsuit, 40mg ANDA lawsuit, non-Orange Book patent litigation, market shift, and copay assistance.
  • Court struck foreign allegations from the complaint.
  • Surviving claims: DAW campaign (false statements to doctors), exclusionary agreements with PBMs, and the 2020 reclassification petition/lawsuit.
  • Lanham Act claim (Count II) and state law claims (Counts III-VI) also survive.
  • No damages awarded; ruling is on motion to dismiss, not final judgment.

Financial Impact

The ruling eliminates several theories that could have resulted in significant damages if proven. The surviving claims are narrower, reducing the overall litigation risk. No specific dollar amount was awarded or stated in the opinion.

litigation riskpotential damages

Risk Factors

  • Surviving claims (DAW campaign, PBM agreements, 2020 reclassification) could still lead to liability after discovery.
  • Mylan may appeal the dismissal of certain claims, though interlocutory appeal is unlikely.
  • Discovery may reveal additional damaging facts that could expand the case.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-2kgjc53a-TEVA

Track record

61 reports on TEVA

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 14 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
  2. Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
  5. Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
  6. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  7. Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  9. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
  10. Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
Showing 10 of 61

US Market Status

Market Closed · Opens in 8h 24m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published Jul 3, 2026